Darolutamide

Introduction Overview

Generic Name

darolutamide

Brand Name

Nubeqa

Dosage Form

oral tablet

Drug Class

Antiandrogens; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Darolutamide is rapidly absorbed following oral administration of Nubeqa tablets. Peak plasma concentrations (Cmax) are typically reached within 4 hours post-dose when taken with food. The bioavailability of darolutamide is significantly enhanced by food intake, thus it is recommended to administer Nubeqa with meals to maximize systemic exposure. The absolute bioavailability has not been precisely determined but is considered adequate to achieve therapeutic plasma levels. Factors such as gastric pH alteration appear to have minimal impact on absorption.

Distribution:
Darolutamide exhibits moderate plasma protein binding, primarily to albumin and alpha-1-acid glycoprotein, with an unbound fraction that allows effective tissue penetration. The volume of distribution is moderately large, indicating extensive distribution into peripheral tissues, including prostate tumor cells. Due to its structure, darolutamide poorly penetrates the blood-brain barrier, which may contribute to a favorable central nervous system side effect profile compared to other androgen receptor antagonists. Darolutamide's distribution pattern supports its effectiveness in targeting androgen receptors in prostate tissue.

Metabolism:
Darolutamide is metabolized predominantly in the liver via oxidative pathways involving cytochrome P450 enzymes, especially CYP3A4. It also undergoes direct glucuronidation by UGT1A9 and UGT1A1 enzymes to inactive metabolites. The two main circulating plasma components are the parent compound darolutamide and its pharmacologically active keto-darolutamide metabolite, which contributes to the drug's therapeutic effects. The metabolism shows stereoselectivity and is influenced by hepatic enzyme polymorphisms. The interplay of these pathways allows for balanced clearance with minimal accumulation on chronic dosing.

Elimination:
Darolutamide and its metabolites are eliminated via both renal and fecal routes. Approximately equal proportions are excreted renally and biliary/fecally as metabolites or unchanged drug. The terminal elimination half-life is around 20 hours, supporting twice-daily dosing regimens. Darolutamide’s clearance does not significantly alter in mild to moderate hepatic or renal impairment, but caution is advised in severe organ dysfunction. Steady-state concentrations are typically achieved within one week of dosing, with no significant drug accumulation beyond steady state in normal renal and hepatic function.

Dosage Forms

Available Dosage Forms:
- Oral film-coated tablets: 300 mg each.

Dosages for Adults and Adolescents:
- The standard recommended adult dose for prostate cancer is 600 mg twice daily, administered as two 300 mg tablets taken orally with food.
- For patients without prior orchiectomy or androgen deprivation therapy, concurrent administration of a gonadotropin-releasing hormone (GnRH) analog is recommended to maintain castrate levels of testosterone.
- In metastatic castration-sensitive prostate cancer (mCSPC) treated with Nubeqa combined with docetaxel, the first cycle of docetaxel should be administered within 6 weeks after starting Nubeqa.

Specific Patient Populations:
- Pediatric use is not established; Nubeqa is not recommended for individuals younger than 18 years.
- Safety and dosage adjustments in patients with hepatic or renal impairment are not fully established; caution is warranted in patients with known liver or kidney disease.
- Not recommended for use in females due to potential for fetal harm.
- No special dosing adjustments are specified for elderly patients; standard dosing applies.

Mechanism Of Action

Nubeqa (darolutamide) is a potent, selective androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the androgen receptor. By competitively inhibiting the binding of androgens such as testosterone and dihydrotestosterone, darolutamide prevents receptor activation, nuclear translocation, and the subsequent transcription of androgen-responsive genes critical for prostate cancer cell growth and survival.

At the molecular level, darolutamide not only blocks androgen binding but also impedes AR dimerization and AR-DNA binding, which are essential steps for receptor-mediated transcriptional activity. This comprehensive inhibition disrupts androgen-driven proliferation, inducing apoptosis and cell cycle arrest in malignant prostate cells.

Unlike other antiandrogens, darolutamide has distinct structural properties that confer minimal penetration across the blood-brain barrier. This results in reduced central nervous system-related side effects, such as seizures or cognitive disturbances, which are occasionally observed with other AR inhibitors like enzalutamide and apalutamide. This pharmacologic profile also reduces drug-drug interactions and limits adverse effects.

Clinical studies demonstrate that darolutamide effectively delays metastasis and progression in non-metastatic castration-resistant prostate cancer (nmCRPC) and improves survival outcomes in metastatic castration-sensitive prostate cancer (mCSPC). Its mechanism allows for use both as monotherapy and in combination with agents such as docetaxel or GnRH analogs to optimize androgen deprivation and tumor control.

Pharmacological Actions

Selective androgen receptor antagonist activity.
Inhibition of androgen receptor signaling pathways in prostate cancer cells.
Reduction of androgen-driven gene expression critical for tumor growth.
Delayed progression of non-metastatic castration-resistant prostate cancer.
Enhanced survival in metastatic castration-sensitive prostate cancer when combined with standard therapies.
Blockade of AR nuclear translocation and DNA binding.
Apoptosis induction and inhibition of prostate cancer cell proliferation.
Reduced central nervous system penetration compared to other antiandrogens, minimizing CNS side effects.
Modulation of hormonal pathways involved in prostate cancer pathogenesis.
Pharmacokinetic properties favor maintaining therapeutic plasma levels with twice-daily dosing.

Therapeutic Or Clinical Uses

Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men who have failed medical or surgical castration therapies.
Management of metastatic castration-sensitive prostate cancer (mCSPC) either as monotherapy or in combination with docetaxel chemotherapy.
Use as an adjunct to gonadotropin-releasing hormone (GnRH) analogs or after bilateral orchiectomy to maintain androgen deprivation.
Delay in metastasis development and progression-free survival extension in prostate cancer patients.
Option for patients intolerant or unsuitable for other androgen receptor inhibitors due to its favorable CNS safety profile.
Component of combination therapy regimens aiming to improve overall survival in advanced prostate cancer.
Treatment of prostate cancer patients with biochemical recurrence and rising PSA levels despite castrate testosterone.
Therapeutic choice for patients requiring a non-CNS penetrant antiandrogen to minimize cognitive side effects.

Side Or Adverse Effects

Fatigue and asthenia, frequently reported but generally manageable.
Musculoskeletal pain including pain in arms, hands, legs, or feet.
Rash presenting as a dermatologic reaction.
Neutropenia or low white blood cell counts which may increase infection risk.
Elevated liver enzymes indicating possible hepatic dysfunction.
Gastrointestinal symptoms such as nausea and diarrhea, occasionally severe.
Urinary symptoms including painful or difficult urination and hematuria (blood in urine).
Cardiovascular signs such as slow heart rate, weak pulse, and hypotension.
Allergic reactions including urticaria (hives), facial or throat swelling, and respiratory difficulties.
Signs of blood clots in the lungs (pulmonary embolism) presenting with chest pain, cough, wheezing, or hemoptysis.
Infections of the lung manifesting as fever, chills, cough, and shortness of breath.
When combined with docetaxel: constipation, decreased appetite, hemorrhage, weight gain, hypertension, anemia, hyperglycemia, lymphopenia, neutropenia, elevated AST and ALT, and hypocalcemia.
Headache and blurred vision, potentially related to vascular changes or hypertension.
Potential for miscarriage or fetal harm when administered during pregnancy.
Rare but severe adverse events may delay cancer treatment and require medical intervention.

Precautions

Assess liver and kidney function prior to and during treatment due to potential impairment impact.
Not recommended for use in women or children; contraindicated in females due to fetal risk.
Effective contraception must be used during treatment and for at least one week after the last dose to prevent pregnancy.
Monitor for signs of allergic reactions and severe hypersensitivity.
Caution in patients with a history of cardiovascular or thromboembolic disorders.
Regular blood counts and liver function tests recommended to detect hematologic or hepatic toxicity early.
Patients should be counseled about potential fatigue and its impact on activities such as driving or operating machinery.
Use with caution when combined with other therapies that affect bone marrow or hepatic function.
Consider drug-drug interactions that may alter darolutamide plasma levels or pharmacodynamics.
Dose adjustments may be necessary in patients with severe hepatic or renal impairment, though data are limited.
Ensure adherence to concurrent hormonal therapy such as GnRH analogs if castration is not achieved surgically.
Patients should be advised about symptoms of blood clots or infections for prompt evaluation.
Avoid abrupt discontinuation without medical advice to prevent disease progression.
Store medication properly in a dry environment at room temperature with container tightly closed.

Warnings

Darolutamide may cause fetal harm or miscarriage; not to be used by women who are or may become pregnant.
Patients should inform all healthcare providers of their use of Nubeqa due to potential for significant drug interactions.
Risk of severe allergic reactions including anaphylaxis necessitating immediate emergency care.
Potential for serious cardiovascular events; monitor for slow heart rate, syncope, or symptoms suggestive of arrhythmia.
Signs of blood clots, such as sudden chest pain or respiratory distress, require urgent evaluation.
Use caution with concomitant medications that may prolong QT interval or affect CYP3A4 activity.
Patients with hepatic or renal impairment may experience increased drug exposure and adverse effects.
Cancer treatment may need to be delayed or modified in response to severe side effects or hematologic abnormalities.
Avoid use in pediatric populations and females; safety and efficacy not established.
Store medicine securely out of reach of children to prevent accidental ingestion.
Do not crush, chew, or break tablets to ensure proper absorption and reduce irritation.
Missed doses should be taken as soon as remembered unless close to the next scheduled dose; avoid doubling doses.
Overdose requires prompt medical attention due to potential for serious toxicity.
Patients are advised to maintain consistent follow-up for monitoring therapy effectiveness and side effects.

Contraindication

Hypersensitivity to darolutamide or any components of the formulation.
Use in women who are or may become pregnant due to teratogenic risk.
Patients with known severe hepatic impairment due to lack of safety data.
Use in pediatric patients under 18 years of age is contraindicated.
Concurrent use with strong CYP3A4 inducers without medical supervision may result in subtherapeutic drug levels.
Known history of severe allergic reactions to similar androgen receptor antagonists.
Use should be avoided in patients with active severe infections or conditions precluding therapy continuation.
Contraindicated in patients with bleeding disorders who are at increased risk of hemorrhage.
Patients with untreated or uncontrolled cardiovascular disease may be at heightened risk during therapy.
Concurrent use with medications contraindicated due to significant interactions impacting darolutamide metabolism.
Known hypersensitivity to excipients contained in the tablet formulation.

Drug Interactions

Darolutamide is metabolized primarily by CYP3A4; strong CYP3A4 inhibitors (e.g., ketoconazole) can increase plasma concentrations, necessitating caution.
Strong CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce darolutamide efficacy by decreasing its systemic exposure.
Darolutamide may induce cytochrome P450 enzymes, potentially decreasing plasma levels of concomitant drugs metabolized by CYP2C9 and CYP2C19.
Concomitant use with anticoagulants (e.g., warfarin) requires close monitoring of coagulation parameters due to potential interaction.
Co-administration with medications that prolong QT interval requires caution and cardiac monitoring.
Darolutamide may alter the pharmacokinetics of drugs with narrow therapeutic windows metabolized by CYP3A4.
Interactions with GnRH analogs are common, but these are standard concurrent therapies and well tolerated.
Avoid use with drugs that may exacerbate QT prolongation or have additive cardiotoxic effects.
Potential interactions with herbal supplements or over-the-counter medications that affect CYP450 enzymes.
Monitoring of blood glucose and serum electrolytes is recommended due to reported metabolic effects in combination therapy.
Dose adjustments of concomitant medications may be necessary when administered with darolutamide.
Patients should inform healthcare providers of all medications, including vitamins and herbal products, to prevent interactions.
Darolutamide does not significantly inhibit or induce P-glycoprotein, reducing the risk of interaction via this route.
No significant interaction with food observed aside from enhanced bioavailability when taken with meals.

Preparations Of The Drug

Darolutamide is supplied as 300 mg film-coated oral tablets designed for twice-daily administration.
Tablets are film-coated to enhance swallowing and stability; should be taken whole without crushing or chewing.
Packaged in bottles with desiccants to protect from moisture and degradation.
Available only by prescription for oral use in prostate cancer management.
Storage recommended at room temperature (20°C to 25°C), protected from excessive moisture and heat.
Supplied in quantities appropriate for dosing cycles aligned with cancer treatment protocols.
No intravenous or alternate routes of administration are currently approved.
Labeling includes detailed dosing instructions, warning information, and patient guidance on food intake.
Accompanying patient information leaflets provide education on potential side effects and precautions.
Manufactured under stringent regulatory standards ensuring potency and purity.
Not compatible with crushing or breaking due to altered pharmacokinetics and patient safety concerns.
Handled in compliance with chemotherapy safety standards to prevent inadvertent exposure.
Disposal guidelines recommend appropriate measures for unused or expired product to minimize environmental impact.
No currently marketed generic versions; brand name Nubeqa is supplied by Bayer Healthcare.